The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Abstract
Background Most patients with obsessive-compulsive disorder (OCD) show only partial reduction of symptoms with standard therapy. Recent imaging data suggests glutamatergic dysfunction in the corticostriatal pathway in OCD. We investigated the efficacy of augmentation therapy with riluzole, a glutamate-modulating agent, in treatment-resistant OCD.Methods Thirteen patients aged between 18 and 65 years with a primary diagnosis of OCD that had proven resistant to standard treatment were treated with the addition of riluzole to their existing pharmacotherapy. Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Hamilton Depression Inventory (HAM-D), and Hamilton Anxiety Inventory (HAM-A) scores were obtained weekly.Results Thirteen treatment-resistant OCD patients received riluzole 50 mg twice a day. Y-BOCS scores improved significantly over time. Of 13 patients, 7 (54%) demonstrated a >35% reduction in Y-BOCS scores, and 5 (39%) were categorized as treatment responders. HAM-D and HAM-A scores for the group also significantly improved over time. Riluzole was well tolerated with no serious adverse effects noted.Conclusions Riluzole appears to have significant antiobsessional, antidepressant, and antianxiety properties. The addition of this agent may be of practical clinical benefit in patients with OCD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BDZs, which have been in clinical use for decades, not only exhibit rapid anxiolytic effects, but also have sedative, amnestic, anticonvulsant, muscle relaxant and addictive properties (Coric et al., 2005;Engin et al., 2018).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005
In the citing paper
“Riluzole was shown to reduce clinical symptoms in adults with treatment-refractory OCD when used as add-on to existing pharmacotherapy, including SSRIs and antipsychotics (Coric et al., 2005;Pittenger et al., 2015).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Coric et al., 2005
Citations
Cites
Applied Mixed Models in Medicine
Brown, H., & Presco, R. (2000) · Technometrics · doi:10.1080/00401706.2000.10485742 · Cited by 1,699
Gueorguieva, R., & Krystal, J. H. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.3.310 · Cited by 1,529
Magistretti, P. J., Pellerin, L., Rothman, D. L., & Shulman, R. G. (1999) · Science · doi:10.1126/science.283.5401.496 · Cited by 1,170
Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients With Major Depression
Sanacora, G., Gueorguieva, R. V., Epperson, C. N., Wu, Y., Appel, M., Rothman, D. L., Krystal, J. H., & Mason, G. F. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.7.705 · Cited by 796
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 562
Neurobiology of Mental Illness
(2011) · Oxford University Press eBooks · doi:10.1093/med/9780199798261.001.0001 · Cited by 523
Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13 C NMR
Shen, J., Petersen, K. F., Behar, K. L., Brown, P., Nixon, T. W., Mason, G. F., Petroff, O. A. C., Shulman, G. I., Shulman, R. G., & Rothman, D. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.8235 · Cited by 462
The Physicians' Desk Reference
Cohen, J. S. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440120021003 · Cited by 430
Riluzole inhibits the persistent sodium current in mammalian CNS neurons
Urbani, A., & Belluzzi, O. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00242.x · Cited by 381
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Lebon, V., Petersen, K. F., Cline, G. W., Shen, J., Mason, G. F., Dufour, S., Behar, K. L., Shulman, G. I., & Rothman, D. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01523.2002 · Cited by 371
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J. A., Sporn, J., Denicoff, K. K., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 327
Jenike, M. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031002 · Cited by 260
Success and failure in the behavioral treatment of obsessive-compulsives.
Foa, E. B., Grayson, J. B., Steketee, G. S., Doppelt, H., Turner, R. M., & Latimer, P. R. (1983) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.51.2.287 · Cited by 258
ROSENBERG, D. R., MIRZA, Y., RUSSELL, A., TANG, J., SMITH, J. M., BANERJEE, S. P., BHANDARI, R., ROSE, M., IVEY, J., BOYD, C., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000132812.44664.2d · Cited by 246
Success and failure in the behavioral treatment of obsessive-compulsives.
Foa, E. B., Grayson, J. B., Steketee, G. S., et al. (1983) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.51.2.287 · Cited by 202
Overbeek, T., Schruers, K., Vermetten, E., & Griez, E. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1204 · Cited by 196
Clinical Studies Implementing Glutamate Neurotransmission in Mood Disorders
Sanacora, G., Rothman, D. L., Mason, G. F., & Krystal, J. H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.018 · Cited by 158
Jenike, M. A. (1983) · Comprehensive Psychiatry · doi:10.1016/0010-440x(83)90098-6 · Cited by 143
Treatment of obsessive‐compulsive disorder in patients who have comorbid major depression
Abramowitz, J. S. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20078 · Cited by 121
Coric, V., Milanovic, S. M., Wasylink, S., Patel, P., Malison, R. T., & Krystal, J. H. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1396-z · Cited by 118
McGrath, M. J., Campbell, K. M., Parks, C. R., & Burton, F. H. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02646-9 · Cited by 95
Effects of riluzole on electrically evoked neurotransmitter release
Jehle, T., Bauer, J., Blauth, E., Hummel, A., Darstein, M., Freiman, T. M., & Feuerstein, T. J. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703424 · Cited by 82
Neurobiology of Mental Illness
Paradiso, S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.5.829 · Cited by 79
Riluzole Augmentation for Treatment-Resistant Depression
Sanacora, G., Kendell, S. F., Fenton, L. R., Coric, V., & Krystal, J. H. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2132 · Cited by 72
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Other agents that have been studied as adjunctive therapy for treatment-resistant OCD include celecoxib [777], granisetron [778], IV ketamine [779,780], ondansetron [784,785], N-acetylcysteine [786,787] (all Level 2), and riluzole (Level 3) [788,789].”
BackgroundAbramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 887
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 593
Metadata
- Authors
- Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., Malison, R. T., & Krystal, J. H.
- Affiliations
- Yale University (US)
- ORCID
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 58
- Issue
- 5
- Pages
- 424-428
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1982538263
- Cited by
- 314
- References
- 25
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 5 · 2017: 15 · 2016: 15 · 2015: 21 · 2014: 21 · 2013: 22 · 2012: 23
- FWCI
- 25.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k05aa014906-03)
- National Institute on Alcohol Abuse and Alcoholism (K05 AA 14906-01)
- National Center for Research Resources (M01RR000125, M01 RR-00125)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- riluzole, treatment-resistant OCD, augmentation therapy, glutamate modulation, glutamatergic dysfunction, corticostriatal pathway, antidepressant effects, anxiolytic effects, adverse effects
- MeSH terms
- Adult, Drug Resistance, Female, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Time Factors, Treatment Outcome, Excitatory Amino Acid Antagonists, Riluzole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
